CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ombitasvir/paritaprevir/ritonavir and dasabuvir

Last Updated: December 3, 2014
Result type: Reports
Project Number: SR0406-000
Product Line: Reimbursement Review

Generic Name: Ombitasvir/paritaprevir/ritonavir and dasabuvir

Brand Name: Holkira Pak

Manufacturer: AbbVie Corporation

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 18, 2015

Recommendation Type: List with clinical criteria and/or conditions